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Edited by Robert BaroukiAbstract We here provide deﬁnitive evidence that ginsenoside-
Rg1, the pharmacologically active component of ginseng, is a
functional ligand of the glucocorticoid receptor (GR) as deter-
mined by ﬂuorescence polarization assay. Rg1 increased the
phosphorylation of GR, phosphatidylinositol-3 kinase (PI3K),
Akt/PKB and endothelial nitric oxide synthase (eNOS) leading
to increase nitric oxide (NO) production in human umbilical vein
endothelial cell. Rg1-induced eNOS phosphorylation and NO
production were signiﬁcantly reduced by RU486, LY294,002,
or SH-6. Also, knockdown of GR completely eliminated the
Rg1-induced NO production. This study revealed that Rg1 can
indeed serve as an agonist ligand for GR and the activated GR
can induce rapid NO production from eNOS via the non-tran-
scriptional PI3K/Akt pathway.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Panax Ginseng C.A. Meyer and its related species have been
used as health tonics for centuries in Chinese medication. Gin-
senosides, the pharmacologically active components found in
ginseng, are triterpenoid saponins that are broadly classiﬁed
into 20(S)-protopanaxatriols (PPT) and 20(S)-protopanaxadi-
ols (PPD) [1]. Ginsenoside-Rg1, a PPT (see Fig. 5A), has been
demonstrated to trigger transcriptional activation of a gluco-
corticoid responsive element (GRE)-containing reporter gene,
suggesting that Rg1 can activate the glucocorticoid receptor
(GR) [2]. Recently, glucocorticoids (GCs) have been reported
to activate the phosphatidylinositol-3 kinase (PI3K)/Akt path-Abbreviations: GR, glucocorticoid receptor; GC, glucocorticoid; GRE,
glucocorticoid responsive element; Dex, dexamethasone; eNOS, endo-
thelial nitric oxide synthase; NO, nitric oxide; HUVEC, human umb-
ilical vein endothelial cell; PI3K, phosphatidylinositol-3 kinase; PKB,
protein kinase B; NR, nuclear receptor; LBD, ligand-binding domain
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doi:10.1016/j.febslet.2006.04.080way after binding to the GR [3]. PI3K/Akt pathway is a crucial
regulator in cell proliferation, cell-cycle progression, and a
mediator of cellular survival [4]. The activated PI3K/Akt path-
way leads to phosphorylation of endothelial nitric oxide syn-
thase (eNOS) and increases the production of nitric oxide
(NO) [5]. NO-related endothelial proliferation and angiogene-
sis were shown to be part of the activities of Rg1 [6]. To eluci-
date the role of the GR in Rg1-induced NO production, we
have examined the state of GR activation and the downstream
activation pathways of PI3K, Akt/protein kinase B (PKB) and
eNOS in human umbilical vein endothelial cells (HUVEC). In
addition, a molecular docking study of Rg1 to the GR was also
performed. This work can provide molecular basis for the di-
verse activities of ginseng.2. Materials and methods
2.1. Materials
Culture medium M199 and endothelial cell growth supplement
(ECGS) were purchased from Sigma. Foetal bovine serum (FBS)
was from Gibco. RU486, LY294,002 and ICI182,780 were from Sig-
ma. SH-6 and L-NMMA was from Calbiochem and Cayman, respec-
tively. Anti-GRa was from Santa Cruz Biotechnology. Anti-phospho-
GR (Ser211) and anti-phospho-PI3 kinase p85 were from Cell Signal-
ing. Anti-PI3 kinase p85, anti-Akt1/PKBa, anti-phospho-Akt1/PKBa
(Ser473), anti-eNOS/NOSIII and anti-phospho-eNOS (Ser1177) were
from Upstate. Anti-b-actin was from Sigma. Alexa Fluor 488 anti-rab-
bit IgG (Molecular Probe) and anti-rabbit IgG HRP (Zymed) were
used for immunocytochemistry and immunoblotting, respectively.
Small interfering RNA (siRNA) was custom-designed and purchased
from Dharmacon (M-003424-02).
2.2. HUVEC culture conditions
HUVEC (Clonetics) were grown in M199 supplemented with 20%
FBS, 20 lg/ml ECGS, 90 U/ml Heparin (Sigma), 1% penicillin–strepto-
mycin–neomycin (PSN, Gibco) and 50 ng/ml amphotericin B (Sigma).
Cultures were maintained at 37 C in humidiﬁed CO2 incubator (5%
CO2). HUVEC were used at passages 2–8.
2.3. NO production assay
HUVEC were seeded in a 96-well plate at 2 · 104 cells/well. Rg1 of
various concentrations was prepared in serum-free medium. The con-
centrations of NO2 and NO

3 in the culture medium were measured
with the NO Detection Kit (Assay Design Inc.) by monitoring the opti-
cal density at 540 nm spectrophotometrically (iEMS analyzer, Labsys-
tems). HUVEC were incubated with diﬀerent concentrations of Rg1 at
37 C for indicated treatment intervals. HUVEC were also pre-incu-
bated with various antagonists/inhibitors: 10 lM RU486, 10 lM
LY294,002, 20 lM SH-6, and 20 lM L-NMMA, respectively, eachblished by Elsevier B.V. All rights reserved.
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Fig. 1. Induction of NO production in HUVEC. (A) Cells were treated
with a 15-fold range of Rg1 concentration for 60 min. (B) The time
proﬁle of NO production after 150 nM Rg1 treatment. The activity of
NOS was quantiﬁed by measuring NO2 and NO

3 concentrations in
serum-free culture media. Total NO production was calculated from a
calibration curve generated from standards provided by the manufac-
turer and normalized by the protein content of the corresponding wells
(N = 3; ±S.D.). All data were signiﬁcantly diﬀerent from control at a
value of P 6 0.05.
3212 K.W. Leung et al. / FEBS Letters 580 (2006) 3211–3216for 30 min with or without 150 nM Rg1 at 37 C. Dexamethasone
(Dex) (500 nM) acted as positive control. Concentrations of NO pro-
duced were calculated according to the calibration curve in each exper-
iment and expressed as nanomoles per microgram protein (±standard
deviation (S.D.)).
2.4. siRNA transfection
siRNA duplex oligo targeting GR mRNA was transfected with
siLenfect (Invitrogen) at 5 nM into HUVEC. Concentrations of NO
produced after 30 min treatment of Rg1 (150 nM) or Dex (500 nM)
were estimated according to the method mentioned above.
2.5. Western blot analysis
Total cellular protein was obtained by lysing cells with lysis buﬀer
(Novagen) supplemented with phosphatase and protease inhibitor
cocktail (Merck). SDS–PAGE resolved protein bands were transferred
to nitrocellulose membranes (Amersham). After blocking with 5%
skimmed milk, the membrane was incubated with primary antibodies
(1:1000 dilution) for 3 h, followed by horseradish peroxidase-conju-
gated IgG (1:2000 dilution). Target proteins were visualized with en-
hanced chemiluminescence reagents (BioRad). Semi-quantiﬁcations
were performed with densitometric analysis by Metamorph software.
2.6. GR competitive ligand-binding assays
Commercially available GR competitive binding assay was used
(Invitrogen). Serial 2-fold dilution of Dex (1 lM to 0.9 nM) and
Rg1 (2 lM to 1.8 nM) were competed with Fluormone, a proprietary
ﬂuorescent GC ligand provided in the kit, for binding to the human
GR. The ﬂuorescence polarization was measured by a PTI Fluores-
cence Lifetime Scanning Spectrometer. Negative (without any ligand;
0% competition) and positive (1 mM Dex; 100% competition) con-
trols delimited the ﬂuorescence polarization range. IC50 is deﬁned
as the concentration of a test compound that causes a half-maximum
shift in polarization. The equilibrium dissociation constant (Kd) is
the concentration of the competing ligand occupying half of the
binding sites in the absence of the tracer ligand. The equilibrium
binding curves were ﬁtted with a two-state one-site competition
model.
2.7. Translocation of phosphorylated GR
Images of the phosphorylated GR in HUVEC were collected with a
Zeiss LSM-510 multi-tracking laser scanning confocal microscope
(Carl Zeiss SAS, Frankfurt, Germany) for translocation study. HU-
VEC (5 · 104 cells) seeded on 13-mm diameter coverslips were ﬁxed
with 4% paraformaldehyde and incubated in anti-phospho-GR
(Ser211) antibody with 0.1% Triton X-100 (Chemicon) and 2% normal
goat serum (Gibco) for 3 h, followed by incubating in Alexa Fluor
488 in dark for 2 h. The coverslips were mounted with DAKO mount-
ing medium. Images were captured (63·) within 72 h. For each treat-
ment, 50 cells were analyzed and the ratio of nucleus/cytoplasm
ﬂuorescence intensity (RN/C) was calculated.
2.8. Statistical analysis
Numerical results were analyzed using one-way ANOVA with Dun-
can post hoc test. Values shown are means of at least N = 3 experi-
ments with ±S.D. Diﬀerences were considered statistically signiﬁcant
at a value of P 6 0.05. Data signiﬁcantly diﬀerent from control was
marked with * in the ﬁgures.3. Results
3.1. Rg1 increases NO production
The production of NO by HUVEC was increased by treat-
ment with Rg1 over a 15-fold dose range (Fig. 1A). Based
on this ﬁnding, HUVEC were challenged with 150 nM Rg1
and the time proﬁle of NO production was monitored for
60 min. An immediate linear rise in the total NO level was de-
tected followed by a plateau after 10 min (Fig. 1B). Using Wes-
tern blotting, the phosphorylation of eNOS at Ser1177 inresponse to Rg1 treatment was detected. An approximately
2.5-fold increase in the phosphorylated form of eNOS was de-
tected as early as 10 min and this trend continued to increase
up to 60 min after the exposure of HUVEC to 150 nM Rg1
(Fig. 2A). This provides direct evidence that Rg1 rapidly acti-
vates eNOS in HUVEC.
3.2. Activation of eNOS via the GR and PI3K/Akt pathway
The upstream phosphorylation of the GR (Ser211), PI3K
p85-subunit and Akt/PKB (Ser473) were also found to increase
during the 60 min duration of exposure to 150 nM Rg1 as
determined by Western blotting (Fig. 2B). The phosphoryla-
tion of GR was peaked at 10 min and dropped back to the base
level at 60 min. The phosphorylation of PI3K and Akt/PKB,
however, were more sustainable after reaching their maximum
at 15 and 30 min, respectively. These results indicated a
sequential activation from the GR to the PI3K/Akt pathway.
The Rg1-induced eNOS phosphorylation at Ser1177 was abol-
ished by the GR antagonist RU486; PI3K inhibitor
LY294,002; and Akt/PKB inhibitor SH-6 (Fig. 3). Also, the
production of NO was diminished to the baseline level in the
presence of RU486 (Fig. 4). However, the Rg1-induced NO
production was unaﬀected by an estrogen receptor (ER) antag-
onist ICI182,780 (10 lM) (Fig. 4),. Moreover, knockdown of
the GR by siRNA completely eliminated the Rg1-induced
NO production (Fig. 4).
AB
Fig. 2. Phosphorylation of signaling molecules after treatment with
Rg1 over a time frame of 60 min. (A) Phosphorylated eNOS (Ser1177)
detected by speciﬁc antibody was increased after 150 nM Rg1
treatment, while total eNOS had no change in quantity. (B)
Phosphorylated forms of GRa (Ser211), PI3K and Akt/PKB
(Ser473) were also found to increase after treatment with 150 nM
Rg1 with no change in the respective total form. Protein loading was
normalized by b-actin.
Fig. 3. Inhibition of eNOS phosphorylation at Ser1177 with diﬀerent
inhibitors/antagonists of the PI3K/Akt pathway. HUVEC pre-treated
with indicated inhibitors/antagonists for 30 min were incubated with
Rg1 (150 nM) for another 30 min. The phosphorylated form of eNOS
(Ser1177) was greatly reduced in the presence of inhibitors/ antago-
nists. Protein loading was normalized by b-actin (N = 3; ± S.D.).
B
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Fig. 4. Inhibition of NO production by steroid receptor antagonists.
(A) Eﬃcacy of the siRNA targeting GRa with protein loading
normalized by b-actin. (B) HUVEC pre-treated with RU486 (10 lM)
or ICI182,780 (10 lM) for 30 min were incubated with Rg1 (150 nM)
for another 30 min. RU486, but not ICI182,780, suppressed the NO
production back to the basal level. Also, GRa knockdown inhibited
the Rg1-induced NO production. Total NO production was calculated
from a calibration curve of standards provided by the manufacturer
and normalized by the protein content of the corresponding wells
(N = 5; ±S.D.).
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A competitive ligand-binding assay was performed to study
the speciﬁc binding of Rg1 to the GR using a proprietary ﬂuo-
rescent GC ligand (Fluormone)-recombinant human GR com-
plex. Displacement of Fluormone from the GR-Fluormone
complex by Rg1 results in a decrease in ﬂuorescence polariza-
tion. The shift in polarization is used to determine the relative
speciﬁc aﬃnity of that ligand for the GR. The competitive li-
gand-binding assay indicated that Rg1 is indeed a ligand of
the GR (Fig. 5A). The Kd values for Dex and Rg1 were
3.35 nM (IC50, 10.55 nM; R
2 = 0.99) and 39.40 nM (IC50,
128.50 nM; R2 = 0.98), respectively (Fig. 5A). We speculated
that Rg1 may bind to the same site as of Dex that is the li-
gand-binding domain (LBD) of the GR. Using the crystal
structure of GR–LBD and Dex, we were able to show by mod-
eling the docking of Rg1 to the ligand-binding site in place of
Dex (Fig. 5B). Although the attached glucosyl rings on Rg1
cause steric bumps, this ginsenoside molecule still marginally
ﬁts into the hydrophobic cavity around the LBD even without
signiﬁcant conformational rearrangement of the protein.
3.4. Translocation of the phosphorylated GR
Ligand-activated steroid receptors can elicit both rapid non-
transcriptional and genomic eﬀects. The genomic eﬀects of Rg1
binding to the GR were assessed by monitoring the transloca-
tion of the GR-ligand complexes from cytoplasm to nucleus.
Exposure of HUVEC to Rg1 (150 nM) and Dex (5 lM) re-
sulted in almost 2- and 5-fold increase in the ratio of nucle-
ar/cytoplasmic ﬂuorescent intensity (RN/C), respectively
Fig. 5. (A) The GR-binding assays of Dex and the ginsenoside-Rg1
shown with their structures. The Y-axis is the ﬂuorescence polarization
(mP). For the ginsenosides, the glucosyl groups are abbreviated as
‘‘glu’’. The ﬁtted curves are assumed to be one-site competition
(N = 3). (B) The ginsenoside-Rg1 (yellow) preliminarily docked to the
GR–LBD (molecule 1 of PDB:1P93, [28]) co-crystallized in the
presence of Dex (grey) using ArgusLab [29]. The green cubic box
shown is the region for deﬁning the binding site of the receptor for
docking. The agonistic ligand-binding residues in the LBD (clockwise
from the top left: Q570, N564, C736, T739, Q642, F623, R611) are
rendered in ball-and-stick (white). (a) Only with the ligand-binding
residues shown. (b) The solvent accessible surface (probe radiu-
s = 1.4 A˚) of the protein is included (pink). The docking residues
deﬁned in the green box for docking were excluded in creating the
surface for clarity.
Fig. 6. Translocation of the phosphorylated GRa (Ser211) after
treatment with Rg1. Treated HUVEC immunostained with anti-
phospho-GR (Ser211). The images were captured by confocal micro-
scope (63·) with identical settings. RN/C, the ratio of nuclear/
cytoplasmic ﬂuorescent intensity of 50 cells from each treatment was
calculated. (A) Negative control. (B) 150 nM Rg1 for 30 min. (C)
HUVEC pre-treated with 10 lM RU486 for 30 min, then co-treated
with 150 nM Rg1 for another 30 min. (D) 5 lM Dex for 30 min. The
micrographs showed that the GR was phosphorylated and translo-
cated into the nucleus in the presence of Rg1 or Dex, while the
translocation was abolished by pretreatment with RU486. Scale
bar = 20 lm.
3214 K.W. Leung et al. / FEBS Letters 580 (2006) 3211–3216(Fig. 6). This indicated that both Rg1 and Dex not only en-
hance the phosphorylation of the GR, but also induce the
translocation of the phosphorylated GR into the nucleus. Fur-
thermore, the translocation due to Rg1 was inhibited by the
GR-antagonist RU486 (Fig. 6C). That means the blockade
of the GR by RU486 not only aﬀects the non-transcriptional
pathways of Rg1, but also the transcriptional ones.4. Discussion
GCs are a class of stress-induced steroid hormones that exert
their actions through activation of GR, a member of the nucle-
ar receptor (NR) superfamily [7]. Increasing evidence shows
that activation of the GR triggers non-transcriptional path-
ways that lead to NO production and vasodilation within min-
utes [8]. Clinically, for patients with myocardial infarction
[9,10] and ischaemic stroke [11], high doses of corticosteroids
or Dex were given to activate eNOS and subsequently induce
vasodilation to transiently decrease blood pressure and sys-
temic vascular resistance accompanied by an increase in coro-
nary and cerebral blood ﬂow [9–11]. The current ﬁndings
provide direct evidence that the Rg1 exerts GC-like eﬀects by
acting as a functional ligand of the GR to induce non-tran-
scriptional eﬀect leading to NO production through PI3K/
Akt pathway in endothelial cells.
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sible for NO production in HUVEC [12]. NO is an important
transcellular signaling molecule contributing to anti-tumor
[13], anti-microbial [14], anti-inﬂammatory [15], anti-oxidative
[16] and immunosuppressive activity of macrophages [14–16].
Owing to its vasodilating property, NO plays an important
role in cardiovascular protection [17]. The increased phosphor-
ylation of eNOS (Ser1177) and NO production in HUVEC
after exposure to Rg1 indicated that part of the physiological
eﬀects of Rg1 could be mediated by NO.
Western blot analysis indicated that Rg1 can rapidly activate
GR, PI3K and Akt/PKB. The PI3K/Akt pathway is known as
one of the candidates that are capable of activating eNOS di-
rectly [18]. In the present study, phosphorylation of eNOS and
NO production were abolished by the inhibitors/antagonists:
RU486 [19], LY294,002 [20], or SH-6 [21], whilst ICI182,780
had no eﬀect. Since RU486 can act as a progesterone receptor
(PR) antagonist [22], siRNA targeting GR was used in HU-
VEC in order to preclude the involvement of other NRs in
the Rg1 induction pathway. Our results showed GR knock-
down completely abolished the Rg1-induced NO production.
These data conﬁrmed the predominant involvement of GR
and the PI3K/Akt pathway in the Rg1-induction pathway,
while the ER and PR were not involved.
The activated PI3K phosphorylates phosphatidylinositol-4,5-
bisphosphate (PIP2), resulting in phosphatidylinositol-3,4,5-tri-
phosphate (PIP3) that subsequently binds to Akt/protein kinase
B (Akt/PKB) [23]. Activation of PI3K/Akt pathway is a key step
for diverse biological eﬀects, including cell proliferation, growth,
and survival [24,25]. Therefore, cellular activities brought about
by the Rg1-activated PI3K/Akt pathway via the speciﬁc binding
with the GR warrant further investigations. The present results
showed that Rg1 is able to trigger the rapid non-transcriptional
eﬀects through the GRﬁ PI3Kﬁ Akt/PKBﬁ eNOS.
Upon ligand binding, the GR dissociates from hsp90-based
chaperones, translocates from cytoplasm to nucleus and regu-
lates gene expression by complexing with the GRE [26,27]. We
demonstrated that the translocation of the phospho-GR in
HUVEC was enhanced by Rg1 and Dex by immunoﬂuores-
cence study. The competitive binding assay and the molecular
docking study support the view that Rg1 can exert its genomic
eﬀects by binding to the LBD of the GR.
In view of the steroidal skeleton of the ginsenosides and the
similarity of the side eﬀects of ginseng overdosing to those of
the corticosteroids or estrogens, the hypothesis that ginsenosides
can act as steroid hormones is sustainable. In the present study,
we have clearly demonstrated that Rg1 can act as an agonist for
the GR, leading to transcriptional and non-transcriptional ef-
fects. However, Rg1 represents only one of the major ginseno-
sides in ginseng, the study of the combinatorial interactions
between ginsenosides and the diverse NRs and their eﬀects will
be an important step towards unraveling themystery of ginseng.
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